Several clinical features of prostate cancer, such as tumor cell differentiation or GS and serum PSA, are used in routine clinical practice to stratify men into low-, intermediate-, and high-risk groups for tumor recurrence after local therapy. The gene discussed is KLK3; the disease is prostate carcinoma.